Nitric oxide and pulmonary arterial pressures in pulmonary hypertension

Free Radic Biol Med. 2004 Oct 1;37(7):1010-7. doi: 10.1016/j.freeradbiomed.2004.06.039.

Abstract

Decreased production of vasodilator substances such as nitric oxide (NO) has been proposed as important in development of pulmonary arterial hypertension (PAH). We hypothesize that NO measured over time serves as a non invasive marker of severity of PAH and response to therapy. We prospectively and serially measured exhaled NO and carbon monoxide (CO), a vasodilator and anti-inflammatory product of heme oxygenases, in 17 PAH patients in conjunction with hemodynamic parameters over 2 years. Although pulmonary artery pressures and NO were similar in all patients at entry to the study, NO increased in the 12 individuals who survived to complete the study, and correlated with change in pulmonary artery pressures. In contrast, CO did not change or correlate with hemodynamic parameters. Investigation of NO-oxidant reaction products in PAH in comparison to controls suggests that NO synthesis is impaired in the lung and that reactive oxygen species may be involved in the pathophysiology of pulmonary hypertension. Endogenous NO is inversely related to pulmonary artery pressure in PAH, with successful therapy of PAH associated with increase in NO.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blood Pressure / physiology*
  • Carbon Monoxide / metabolism
  • Female
  • Humans
  • Hypertension, Pulmonary / metabolism*
  • Hypertension, Pulmonary / physiopathology*
  • Hypertension, Pulmonary / therapy
  • Middle Aged
  • Nitric Oxide / metabolism*
  • Prospective Studies
  • Pulmonary Artery / metabolism*
  • Pulmonary Artery / physiopathology*
  • Time Factors

Substances

  • Nitric Oxide
  • Carbon Monoxide